ライフサイエンスコーパス: 1,25-dihydroxyvitamin D

1 emia and inappropriately low serum levels of 1,25-dihydroxyvitamin D.

2 n of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D.

3 one (PTH), insulin-like growth factor 1, and 1,25-dihydroxyvitamin D.

4 ne that catabolizes 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D.

5 y low but is highly induced by its substrate 1,25-dihydroxyvitamin D.

6 ceptors (VDRs), suggesting responsiveness to 1,25-dihydroxyvitamin D.

7 not affected by different concentrations of 1,25-dihydroxyvitamin D.

8 xyvitamin D and the active vitamin D hormone 1, 25-dihydroxyvitamin D.

9 onstrated potent renoprotective activity for 1,25-dihydroxyvitamin D (1,25(OH)(2)D(3)).

10 es, but the interplay between the subsequent 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and 24,25-dihydro

11 The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) enhances innate i

12 y metabolized to its hormonally active form, 1,25-dihydroxyvitamin D (1,25(OH)(2)D), by the 1-hydroxy

13 The product of this enzyme, 1,25-dihydroxyvitamin D (1,25(OH)(2)D), promotes the dif

14 In vitro studies demonstrated 1,25-dihydroxyvitamin D (1,25(OH)(2)VD(3)) increased the

15 oth plasma 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) biomarkers.

16 ion induced by the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D) with subsequent RNA

17 etween yearly 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and FGF23 serum le

18 (PTH) levels (2 degrees HPT), deficiency of 1,25-dihydroxyvitamin D (1,25(OH)2D), and hypocalciuria.

19 , we measured 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), FGF23, and parathy

20 Synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH)(2)D), by renal epithe

21 ciations between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25[OH](2)D) at baseline and t

22 tients with SS asthma were preincubated with 1,25-dihydroxyvitamin D (1,25[OH]2D [VitD]), followed by

23 in levels of 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]2D), parathyroid hormon

24 1,25-dihydroxyvitamin D (1,25[OH]2D3) modulates innate i

25 1,25-Dihydroxyvitamin D (1,25D) analogs engage the vitam

26 dies and mathematical modeling that hormonal 1,25-dihydroxyvitamin D (1,25D) and the vitamin D recept

27 N-gamma) and the calcitropic steroid hormone 1,25-dihydroxyvitamin D (1,25D) are activators of macrop

28 amin D, is converted into the active hormone 1,25-dihydroxyvitamin D (1,25D) by the cytochrome P450 e

29 Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptio

30 factor 23 (FGF23), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25D) predict renal outcomes i

31 fibroblast growth factor 23 (FGF23), reduced 1,25-dihydroxyvitamin D (1,25D), and hypophosphatemia.

32 most biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), is synthesized by CYP27

33 Analogues of hormonal vitamin D, 1,25-dihydroxyvitamin D (1,25D), signal through the nucl

34 ere relatively insensitive to treatment with 1,25-dihydroxyvitamin D (1,25D), the active form of vita

35 mal in early-moderate CKD, despite declining 1,25-dihydroxyvitamin D (1,25D).

36 d Cyp27b1, the enzyme that produces hormonal 1,25-dihydroxyvitamin D (1,25D).

37 ting in synthesis of the pleiotropic hormone 1,25-dihydroxyvitamin D (1,25VD), which regulates over 6

38 tary fat intake (r = 0.29, P = 0.001), serum 1,25 dihydroxyvitamin D [1,25(OH)(2)D] concentrations (r

39 entrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1, 25(OH)(2)D], intact parathyr

40 into 24,25-dihydroxyvitamin D(3) and active 1,25-dihydroxyvitamin D [1,25(OH)(2)D(3)], with subseque

41 Serum concentrations of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] and parathyroid h

42 signaling and increased serum phosphate and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] concentrations in

43 iciency is related to serum 25(OH)D or serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D] concentrations.

44 endent phosphate transport and production of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] in the proximal t

45 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels were low i

46 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels were measu

47 Maternal 25(OH)D, parathyroid hormone, and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] were determined a

48 nd serum calcium, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D [1,25(OH)(2)D], 24,25-dihydroxyv

49 entrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], and parathyroid

50 e circulating 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], and their determ

51 able calcium pool, VO+, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], parathyroid horm

52 anges in serum parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations from

53 Within monocytes, 1,25-dihydroxyvitamin D [1,25(OH)2D] is important for pr

54 Free 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] were lower in obese

55 al VDR, serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], and parathyroid ho

56 s, namely, 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D], have received the

57 D, genetic disorders of its bioactivation to 1,25-dihydroxyvitamin D [1,25(OH)2D], or disorders of vi

58 tamin D metabolism and inhibit production of 1,25-dihydroxyvitamin D [1,25(OH)2D], the active vitamin

59 25(OH)D is activated in the kidneys to 1,25-dihydroxyvitamin D [1,25(OH)2D], which regulates ca

60 of phosphate (inorganic phosphorus, Pi) and 1,25-dihydroxyvitamin D [1,25(OH)2D].

61 c mice with losartan or paricalcitol (19-nor-1,25-dihydroxyvitamin D(2), an activated vitamin D analo

62 rmone-related peptide, prolactin, estradiol, 1,25-dihydroxyvitamin D, 24-hydroxyvitamin D, femoral bo

63 the hypothesis that calciotrophic hormones [1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, and parath

64 1,25-Dihydroxyvitamin D, 25-hydroxyvitamin D, PTH, femor

65 The vitamin D receptor (VDR) ligand, 1,25 dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), reduces pr

66 own that the active metabolite of vitamin D, 1,25 dihydroxyvitamin D(3), stimulates differentiation a

67 In the present study we report that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2) VD)(3)induces OC

68 se (HG, 25 mm) in the presence or absence of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) (25, 50 nm)

69 Given the immunosuppressive role of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its cli

70 that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuc

71 The present study shows that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) arrests ova

72 keletal metabolism by inducing resistance to 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) by a mechan

73 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) can modulat

74 We have shown that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) down-regula

75 The synthesis of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) from its pr

76 o its calciotropic function, the secosteroid 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) has potent

77 The 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone bin

78 function to maintain physiological levels of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) in the kidn

79 ropic effects, the active form of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a potent

80 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a potent

81 Monocyte differentiation induced by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is interrup

82 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the biol

83 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) or Runx2 st

84 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) stimulates

85 n important role in the maintenance of serum 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) under normo

86 CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitam

87 The active metabolite of vitamin D (1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))) is known t

88 The active metabolite of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), and a seri

89 n by fibroblast growth factor 23 (FGF23) and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), and recipr

90 resistance to the active form of vitamin D [1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))] who presen

91 ike multinucleated cell formation induced by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) and parath

92 pothesis that the sunlight-dependent hormone 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is a natur

93 synthesis, we proposed that vitamin D(3) and 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) may protec

94 Osteoclast formation, whether stimulated by 1,25-dihydroxyvitamin D(3) (1,25-D) or by parathyroid ho

95 It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rap

96 differentiate to monocytes by an exposure to 1,25-dihydroxyvitamin D(3) (1,25D(3)), form a complex, a

97 AAT/enhancer-binding protein (C/EBP) beta in 1,25-dihydroxyvitamin D(3) (1,25D(3))-induced monocytic

98 activated with the active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25D(3)).

99 1,25-Dihydroxyvitamin D(3) (1,25D) used to treat human a

100 n active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experim

101 Hormonally active vitamin D(3)-1,25-dihydroxyvitamin D(3) (1,25D3)-acts as a signaling

102 ere additive with that of melatonin whereas, 1,25-dihydroxyvitamin D(3) (IC(50)=10 nM), which by itse

103 a mixture of powdered peanut allergen (PNA), 1,25-dihydroxyvitamin D(3) (VD3), and CpG.

104 that naturally recognizes the small molecule 1,25-dihydroxyvitamin D(3) (vit D).

105 enes in keratinocytes in a similar manner to 1,25-dihydroxyvitamin D(3) [1,25(OH)(2) D(3) ].

106 oups were cultured in vitamin D-deficient or 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] -supplement

107 vestigated mechanisms by which genistein and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] act synergi

108 is regulated by two major calcemic hormones, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and parathy

109 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces the

110 Transcriptional regulation by hormonal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] involves oc

111 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is a princi

112 the 25-hydroxyvitamin D(3)-24-hydroxylase by 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is well est

113 In wild-type mice, inhibition of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] synthesis a

114 te cancer risk by lowering concentrations of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a hormone

115 The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], has a dire

116 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], the active

117 tor that mediates the actions of its ligand, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], which can

118 es a paracellular process, we found that the 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]-activated g

119 e for mediating the biological activities of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].

120 in the spinal cord, so the locally-produced 1,25-dihydroxyvitamin D(3) accumulated and resolved the

121 CaT1 mRNA levels are not responsive to 1,25-dihydroxyvitamin D(3) administration or to calcium

122 D(3)-fed female mice had significantly more 1,25-dihydroxyvitamin D(3) and fewer CYP24A1 transcripts

123 The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D(3) and mediates its actions on g

124 data provide the first in vivo evidence that 1,25-dihydroxyvitamin D(3) and the VDR impact on ductal

125 tamin D(2), 24,25-dihydroxyvitamin D(3), and 1,25-dihydroxyvitamin D(3) could be detected in most sam

126 1,25-Dihydroxyvitamin D(3) differentiation of MM6 cells

127 COS-1 cells with the Src-specific activator 1,25-dihydroxyvitamin D(3) enhanced activity; treatment

128 The bone-specific activation and 1,25-dihydroxyvitamin D(3) enhancement of osteocalcin (O

129 esearch has shown a strong protective effect 1,25-dihydroxyvitamin D(3) in experimental autoimmune en

130 nd TRPV6 null mice responded equally well to 1,25-dihydroxyvitamin D(3) in increasing intestinal calc

131 he vitamin D(3) receptor (VDR), whose ligand 1,25-dihydroxyvitamin D(3) is the biologically active fo

132 Serum calcium and 1,25-dihydroxyvitamin D(3) levels were normal but parath

133 ked reductions in 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) levels, despite upregulation

134 The results also suggest that 1,25-dihydroxyvitamin D(3) may not play a role in this a

135 Finally, stimulation of Lyn expression by 1,25-dihydroxyvitamin D(3) treatment in HL-60 cells, a c

136 The responsiveness of RANKL to 1,25-dihydroxyvitamin D(3) was not elevated in the oster

137 e the antiangiogenic activity of calcitriol (1,25-dihydroxyvitamin D(3)) in vivo and its effect on re

138 Oral calcitriol (1,25-dihydroxyvitamin D(3)) prevented as well as partly

139 with the VDR activating ligand, calcitriol (1,25-dihydroxyvitamin D(3)), resulted in over a 6-fold i

140 Although vitamin D hormone (VDH; 1,25-dihydroxyvitamin D(3)), the active metabolite of vi

141 y of CYP3A4, whose expression was induced by 1,25-dihydroxyvitamin D(3), and of CYP1A1, induced by be

142 growth-inhibited by all-trans-retinoic acid, 1,25-dihydroxyvitamin D(3), and transforming growth fact

143 ing in mouse marrow cultures stimulated with 1,25-dihydroxyvitamin D(3), as well as markers of osteoc

144 n circulating levels of parathyroid hormone, 1,25-dihydroxyvitamin D(3), or fibroblast growth factor

145 and fewer CYP24A1 transcripts, encoding the 1,25-dihydroxyvitamin D(3)-inactivating enzyme, in the s

146 ctive 25-dihydroxyvitamin D(3) to the active 1,25-dihydroxyvitamin D(3).

147 l ligand for the vitamin D receptor (VDR) is 1,25-dihydroxyvitamin D(3).

148 full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3).

149 response to the pro-osteoclastogenic factor 1,25-dihydroxyvitamin D(3).

150 s induced to differentiate by an exposure to 1,25-dihydroxyvitamin D(3); however, its activator in th

151 VDRR: 25-hydroxyvitamin D 34 ng/mL (20-100); 1,25-dihydroxyvitamin D 507 pg/mL.

152 f prostate cancer through reduction of serum 1,25-dihydroxyvitamin D, a potent anti-prostate cancer h

153 The active vitamin D metabolite, 1,25-dihydroxyvitamin D, acting through the vitamin D re

154 irculating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, alopecia persisted in the VDR-n

155 hat encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-dihydroxyvitamin D.

156 showed significantly higher serum levels of 1,25-dihydroxyvitamin D and developed extensive calcific

157 , hyperaldosteronism, and elevated levels of 1,25-dihydroxyvitamin D and Fgf23, consistent with disru

158 We assessed 1,25-dihydroxyvitamin D and other biochemical parameters

159 ke growth factor binding protein 3 but lower 1,25-dihydroxyvitamin D and parathyroid hormone concentr

160 ients, older patients had consistently lower 1,25-dihydroxyvitamin D and phosphate levels (p = .013 a

161 ient cardiac surgery-related fluctuations in 1,25-dihydroxyvitamin D and the aforementioned parameter

162 Exogenous calcitriol (1,25-dihydroxyvitamin D) and high circulating levels of

163 PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D concent

164 PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D concent

165 ns of change in calciotrophic hormones (PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D) in the

166 renal 1-alpha-hydroxylase expression, serum 1,25-dihydroxyvitamin D, and calcium levels than KL(fl/f

167 by hypophosphatemia, decreased production of 1,25-dihydroxyvitamin D, and rickets/osteomalacia.

168 n kidney mass, lower concentrations of serum 1,25-dihydroxyvitamin D, and secondary increases in seru

169 FGF-23, soluble klotho, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and tartrate-resistant acid pho

170 blastic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D appears to be an important posit

171 The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitam

172 e concomitant with increased serum levels of 1,25-dihydroxyvitamin-D, as also observed in the Fgf23(-

173 hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D recepto

174 We investigated whether administration of 1,25-dihydroxyvitamin D (calcitriol) to critically ill p

175 suggests that autocrine/paracrine actions of 1,25-dihydroxyvitamin D complement the classic endocrine

176 lase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral

177 For those with low serum 1,25-dihydroxyvitamin D concentrations (< or =23 pg per

178 Circulating 1,25-dihydroxyvitamin D concentrations among participant

179 baseline and 18 mo postparturition, PTH and 1,25-dihydroxyvitamin D concentrations did not decline,

180 ) but were not significantly correlated with 1,25-dihydroxyvitamin D concentrations.

181 ased levels of serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, consistent with decreased reabs

182 ith prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decreased expression of hepcidin

183 pro- and antiinflammatory cytokine balance, 1,25-dihydroxyvitamin D failed to improve survival.

184 ate 25-hydroxyvitamin D must be converted to 1,25-dihydroxyvitamin D for full biological activity, an

185 king elevations in serum PTH and calcitriol [1,25-dihydroxyvitamin D] in subjects consuming the low-p

186 oid hormone, but administration of exogenous 1,25-dihydroxyvitamin D increased FGF23 levels.

187 e highest in the intestine where it mediates 1,25 dihydroxyvitamin D-induced gene expression.

188 lopecia was not secondary to toxic levels of 1,25-dihydroxyvitamin D interacting with an alternative

189 gate whether the markedly elevated levels of 1,25-dihydroxyvitamin D led to the alopecia, we raised V

190 tabolism was normalized in KO/TG mice: serum 1,25 dihydroxyvitamin D levels were higher in KO/TG mice

191 al bacterial populations, vitamin D receptor:1,25 dihydroxyvitamin D levels, epithelial barrier integ

192 t with hypercalciuria due to increased serum 1,25-dihydroxyvitamin D levels and increased intestinal

193 n with prediagnostic circulating 25(OH)D and 1,25-dihydroxyvitamin D levels and with two VDR single n

194 Low 1,25-dihydroxyvitamin D levels are associated with infla

195 Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with morta

196 mine whether therapies aimed at treating low 1,25-dihydroxyvitamin D levels can improve the outcome i

197 for atherosclerosis, parathyroid hormone, or 1,25-dihydroxyvitamin D levels did not alter these assoc

198 Circulating 1,25-dihydroxyvitamin D levels fluctuate in relation to

199 calcium and parathyroid hormone levels, but 1,25-dihydroxyvitamin D levels that are inappropriately

200 ance for dietary magnesium intake, and serum 1,25-dihydroxyvitamin D levels was able to accurately se

201 (+/- SD) serum total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were 17 +/- 8 ng/mL and 3

202 The 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were significantly higher

203 menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake,

204 h mild hypophosphatemia and/or elevations in 1,25-dihydroxyvitamin D levels.

205 ve TaqI genotype (P = 0.005) and circulating 1,25-dihydroxyvitamin-D levels (P = 0.03) as independent

206 tal calcium, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, magnesium, and markers of bone

207 MA, collagen type I and fibronectin, whereas 1,25-dihydroxyvitamin D markedly suppressed the inductio

208 stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related antibacterial protein

209 7.7% (SE: 3.7%) for each pmol/L increment in 1,25-dihydroxyvitamin D (p = .037).

210 , alkaline phosphatase, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, parathyroid hormone, osteocalci

211 Treatment of neonatal cardiomyocytes with 1,25-dihydroxyvitamin D partially reduced isoproterenol-

212 In addition, studies showed that 1,25-dihydroxyvitamin D rapidly activates signal transdu

213 tive form of vitamin D, and cause hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR).

214 by hyperphosphatemia, elevated production of 1,25-dihydroxyvitamin D, soft tissue calcifications, and

215 In culture, 1,25-dihydroxyvitamin D suppressed high-glucose-induced

216 f phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperp

217 se converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune

218 1,25 dihydroxyvitamin D (VD) has been shown to exert a n

219 1,25-dihydroxyvitamin D (VD) regulates intestinal calciu

220 Circulating 1,25-dihydroxyvitamin D was directly related to glomerul

221 Plasma 1,25-dihydroxyvitamin D was normal, and no alterations i

222 The clinical effectiveness of 1,25-dihydroxyvitamin D was reported in a double-blind,

223 Serum levels of PTH and 1, 25-dihydroxyvitamin D were substantially increased ab

224 culated bioavailable 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were 2.5 +/- 2.0 ng/mL and 6.6 +